×
About 628 results

ALLMedicine™ Immunofixation Center

Research & Reviews  211 results

The potential role of mass spectrometry for the identification and monitoring of patien...
https://doi.org/10.1111/bjh.18226
British Journal of Haematology; Giles HV, Wechalekar A et. al.

May 7th, 2022 - Mass spectrometry (MS) techniques provide a highly sensitive methodology for the assessment and monitoring of paraproteins compared to standard electrophoretic techniques. The International Myeloma Working Group (IMWG) recently approved the use of...

Oligosecretory myeloma with gastrointestinal tract involvement: an unusual presentation...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977735
BMJ Case Reports; Ling VYH, Reddivari S et. al.

Apr 3rd, 2022 - A woman in her 70s with vague gastrointestinal (GI) symptoms and unintentional weight loss was referred to endoscopy clinic for investigation and consideration of GI malignancy. CT of the thorax, abdomen and pelvis showed a suspicious mass in the ...

Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US populatio...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067621
The Lancet. Haematology; El-Khoury H, Lee DJ et. al.

Mar 29th, 2022 - Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is...

Rapidly Enlarging Bullous Plaque
https://www.mdedge.com/dermatology/article/252463/dermatopathology/rapidly-enlarging-bullous-plaque
Marina Kristy Ibraheim, MD, Katherine Martin, MD et. al.

Mar 7th, 2022 - The Diagnosis: Bullous Pyoderma Gangrenosum A bone marrow biopsy revealed 60% myeloblasts, leading to a diagnosis of acute myeloid leukemia (AML). A biopsy obtained from the edge of the bullous plaque demonstrated a dense dermal neutrophilic infil.

Iceland Screens, Treats or Prevents Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT03327597

Mar 2nd, 2022 - Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-protein detected on serum protein electrophoresis ...

see more →

Guidelines  3 results

The evaluation of monoclonal gammopathy of renal significance: a consensus report of th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136169
Nature Reviews. Nephrology; Leung N, Bridoux F et. al.

Dec 5th, 2018 - The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnosti...

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210231
Haematologica Minnema MC, Kimby E et. al.

Oct 21st, 2016 - Bing Neel syndrome is a rare disease manifestation of Waldenström's macroglobulinemia that results from infiltration of the central nervous system by malignant lymphoplasmacytic cells. In this guideline we describe the clinical symptoms, as well a...

Consensus recommendations for standard investigative workup: report of the Internationa...
https://doi.org/10.1182/blood-2010-10-299529
Blood Dimopoulos M, Kyle R et. al.

Feb 5th, 2011 - A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monocl...

see more →

Clinicaltrials.gov  9 results

Iceland Screens, Treats or Prevents Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT03327597

Mar 2nd, 2022 - Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-protein detected on serum protein electrophoresis ...

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT05208086

Jan 26th, 2022 - To evaluate the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in Multiple Myeloma patients. 300 evaluable patients are required. For each of them, both spo...

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT03413800

Aug 16th, 2021 - Myeloma patients in first relapse after sibling or unrelated donor allogeneic transplant willing to participate in this study will be screened for eligibility. After baseline evaluation including BM aspirate for plasma cell count, minimal residual...

ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy
https://clinicaltrials.gov/ct2/show/NCT04513600

Jan 27th, 2021 - The investigators hypothesize that participants with earlier stages (NYHA Class I and Class II) of ATTR wild type and ATTR mutant will demonstrate stabilization of ATTR following 1 year of Tafamidis. The investigators propose to pursue the followi...

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT01248455

Nov 19th, 2019 - Background: Multiple myeloma (MM) is an incurable plasma cell neoplasm with a median survival of 3-4 years. Smoldering multiple myeloma (SMM) is a premalignant plasma cell disorder characterized by monoclonal protein greater than or equal to 3 g/d...

see more →

News  28 results

Rapidly Enlarging Bullous Plaque
https://www.mdedge.com/dermatology/article/252463/dermatopathology/rapidly-enlarging-bullous-plaque
Marina Kristy Ibraheim, MD, Katherine Martin, MD et. al.

Mar 7th, 2022 - The Diagnosis: Bullous Pyoderma Gangrenosum A bone marrow biopsy revealed 60% myeloblasts, leading to a diagnosis of acute myeloid leukemia (AML). A biopsy obtained from the edge of the bullous plaque demonstrated a dense dermal neutrophilic infil.

Pyoderma gangrenosum: Understanding the difficult diagnosis
https://www.mdedge.com/dermatology/article/241535/medical-dermatology/pyoderma-gangrenosum-understanding-difficult
Randy Dotinga

Jun 15th, 2021 - Pyoderma gangrenosum (PG), a rare and painful ulcerative skin disorder, requires special care because “it’s a challenging diagnosis to make” and is frequently linked to serious comorbid conditions, a dermatologist told colleagues. PG is also chall.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Offers Subcutaneous CD38-Directed Antibody to Health Care Providers and Their Multiple Myeloma Patients
https://www.onclive.com/view/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-offers-subcutaneous-cd38-directed-antibody-to-health-care-providers-and-their-multiple-myeloma-patients

Apr 26th, 2021 - Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.1 Nearly five y...

Using PI-based Combinations in RRMM
https://www.onclive.com/view/using-pi-based-combinations-in-rrmm

Apr 2nd, 2021 - Paul G. Richardson, MD: Saad, tell us about your own work with CANDOR, particularly the value of a PI [proteasome inhibitor] combined with a monoclonal antibody. It was pivotal work. Congratulations on the FDA approval very recently. That was terr...

Future of MRD Assessment in NDMM
https://www.onclive.com/view/future-of-mrd-assessment-in-ndmm

Apr 2nd, 2021 - Paul G. Richardson, MD: Regarding MRD [minimal residual disease], Saad, if you could bring up the rear of this section and summarize where you see MRD assessment. As you’ve heard so nicely, MRD is giving us clues to what works best, and there was ...

see more →